Celsius Therapeutics
399 Binney Street
1st Floor
Cambridge
MA
02139
United States
About Celsius Therapeutics
17 articles about Celsius Therapeutics
-
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases
2/27/2023
Celsius Therapeutics today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for a digital oral presentation at the 18th Congress of ECCO.
-
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody for Inflammatory Bowel Disease at 2023 Crohn’s & Colitis Congress
1/19/2023
Celsius Therapeutics today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for oral presentation at the 6th Annual Crohn’s & Colitis Congress, taking place January 19-21, 2023, in Denver, Colorado.
-
Celsius Therapeutics Names Scientific Advisers
9/22/2022
Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.
-
This week's Movers & Shakers includes Tessa and Adial bringing in new CEOs, while other companies strengthened their regulatory and medical teams with key appointments -
Celsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical Officer
8/25/2022
Celsius Therapeutics today announced the appointment of Sarah Grant, M.D., as chief medical officer.
-
Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022
3/24/2022
Celsius Therapeutics provided a summary of recent corporate highlights, including the nomination of its first clinical candidate for inflammatory bowel disease, an additional $83 million in financing and key initiatives for 2022.
-
Celsius Therapeutics raised $83 million in funding, paving the way for several ambitious projects announced in its recently released key initiatives for 2022. -
Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology
7/1/2020
Celsius Therapeutics, a company focused on bringing precision medicine to patients with autoimmunity, cancer and other complex diseases, today announced the signing of three collaboration agreements with the University of Oxford (Oxford, UK), Cleveland Clinic (Cleveland, U.S.) and the LMU University Hospital Munich (Munich, Germany). In each agreement, Celsius will partner with leading academic scientists to access patie
-
Celsius Therapeutics Announces Key Leadership Appointments
5/12/2020
Jeanne Magram, Ph.D., Appointed to Chief Scientific Officer Ren é Russo, Pharm.D., Joins Board of Directors CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer, autoimmunity and other complex diseases, today announced the appointment of Jeanne Magram, Ph.D., to chief scientific officer. Christoph Lengauer, Ph.D., a partner at Third Rock Ventures and co-founder and
-
Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune Checkpoint Therapy Resistance
9/19/2019
Celsius Applying its Single-Cell Genomics Platform Across Multiple Tumor Types and Immuno-Oncology Clinical Trials
-
Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis
7/9/2019
Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study
-
Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial. -
Celsius Therapeutics Appoints Tariq Kassum, M.D., as Chief Executive Officer
6/11/2019
Experienced biopharma leader brings business development, strategy and company-building expertise to accelerate Celsius’ growth
-
Celsius Therapeutics Announces Executive Leadership Team Appointments
5/22/2019
Greg Ryslik, Ph.D., Appointed to Chief Data Officer Michael Boretti, Ph.D., Appointed to Chief Business Officer
-
Celsius Holdings, Inc. Names Edwin Negron-Carballo As Chief Financial Officer To Support Continued Growth
7/31/2018
Experienced Financial Executive Brings Over 30 Years' Experience to Celsius
-
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Celsius Therapeutics for Fully Human Monoclonal Antibody Drug Discovery
6/1/2018
Harbour BioMed announced that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics.
-
The financing was led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and others.